NO923659L - Gp75 som en tumorvaksine for melanom - Google Patents

Gp75 som en tumorvaksine for melanom

Info

Publication number
NO923659L
NO923659L NO92923659A NO923659A NO923659L NO 923659 L NO923659 L NO 923659L NO 92923659 A NO92923659 A NO 92923659A NO 923659 A NO923659 A NO 923659A NO 923659 L NO923659 L NO 923659L
Authority
NO
Norway
Prior art keywords
fragment
stimulating
vaccines
amino acid
nucleic acid
Prior art date
Application number
NO92923659A
Other languages
English (en)
Other versions
NO311366B1 (no
NO923659D0 (no
Inventor
Alan N Houghton
Setaluri Vijayasaradhi
Original Assignee
Sloan Kettering Inst Cancer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23976841&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO923659(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sloan Kettering Inst Cancer filed Critical Sloan Kettering Inst Cancer
Publication of NO923659D0 publication Critical patent/NO923659D0/no
Publication of NO923659L publication Critical patent/NO923659L/no
Publication of NO311366B1 publication Critical patent/NO311366B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y110/00—Oxidoreductases acting on diphenols and related substances as donors (1.10)
    • C12Y110/03—Oxidoreductases acting on diphenols and related substances as donors (1.10) with an oxygen as acceptor (1.10.3)
    • C12Y110/03001—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0055—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10)
    • C12N9/0057—Oxidoreductases (1.) acting on diphenols and related substances as donors (1.10) with oxygen as acceptor (1.10.3)
    • C12N9/0059—Catechol oxidase (1.10.3.1), i.e. tyrosinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/18—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with another compound as one donor, and incorporation of one atom of oxygen (1.14.18)
    • C12Y114/18001—Tyrosinase (1.14.18.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO19923659A 1990-03-22 1992-09-21 Isolert nukleinsyremolekyl som koder for gp75, fremgangsmåte for å fremstille en aminosyresekvens fra samme, samt fremgangsmåtefor å fremstille vaksine NO311366B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US49743190A 1990-03-22 1990-03-22
PCT/US1991/001942 WO1991014775A1 (en) 1990-03-22 1991-03-22 Gp75 as a tumor vaccine for melanoma

Publications (3)

Publication Number Publication Date
NO923659D0 NO923659D0 (no) 1992-09-21
NO923659L true NO923659L (no) 1992-11-06
NO311366B1 NO311366B1 (no) 2001-11-19

Family

ID=23976841

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19923659A NO311366B1 (no) 1990-03-22 1992-09-21 Isolert nukleinsyremolekyl som koder for gp75, fremgangsmåte for å fremstille en aminosyresekvens fra samme, samt fremgangsmåtefor å fremstille vaksine

Country Status (20)

Country Link
US (2) US6168946B1 (no)
EP (2) EP0965640A1 (no)
JP (2) JP3336006B2 (no)
AT (1) ATE187493T1 (no)
AU (1) AU660412B2 (no)
CA (1) CA2078773C (no)
CZ (1) CZ290278B6 (no)
DE (1) DE69131829T2 (no)
DK (1) DK0522078T3 (no)
ES (1) ES2141089T3 (no)
FI (1) FI113786B (no)
GR (1) GR3032804T3 (no)
HU (1) HU218416B (no)
IE (2) IE20000918A1 (no)
NO (1) NO311366B1 (no)
NZ (1) NZ237532A (no)
PL (3) PL169105B1 (no)
PT (1) PT97103B (no)
SK (1) SK282873B6 (no)
WO (1) WO1991014775A1 (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
US7041801B1 (en) * 1995-06-07 2006-05-09 Vanderbilt University Antibodies binding to polypeptides encoded by developmentally-regulated endothelial cell locus-1
US7001600B1 (en) 1996-02-09 2006-02-21 The United States Of America As Represented By The Secretary Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
US7015312B1 (en) 1996-02-09 2006-03-21 The United States Of America As Represented By The Department Of Health And Human Services Antibodies to the protein product encoded by ORF3 of the TRP-1 gene and compositions and kits thereof
US5840839A (en) * 1996-02-09 1998-11-24 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein
US6083703A (en) * 1996-02-09 2000-07-04 The United States Of America As Represented By The Department Of Health And Human Services Identification of TRP-2 as a human tumor antigen recognized by cytotoxic T lymphocytes
WO2001060391A1 (en) * 2000-02-15 2001-08-23 Regents Of The University Of California A universal vaccine and method for treating cancer employing telomerase reverse transcriptase
US6613534B2 (en) 2001-03-20 2003-09-02 Wake Forest University Health Sciences MAP-2 as a determinant of metastatic potential
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
US20030157720A1 (en) * 2002-02-06 2003-08-21 Expression Technologies Inc. Protein standard for estimating size and mass
RU2287578C1 (ru) * 2005-04-22 2006-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Kor, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2287575C1 (ru) * 2005-04-22 2006-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel P, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2287577C1 (ru) * 2005-04-22 2006-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel IL, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
WO2008156655A2 (en) 2007-06-15 2008-12-24 Genelux Corporation Vaccinia virus vectors encoding a sodium-dependent transporter protein for imaging and/or treatment of tumors
US7951370B2 (en) 2008-03-12 2011-05-31 Imclone Llc Anti-TYRP1 antibodies
RU2373280C1 (ru) * 2008-04-24 2009-11-20 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Gus, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2390556C1 (ru) * 2008-12-26 2010-05-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Z, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН
RU2402603C1 (ru) * 2009-02-12 2010-10-27 Государственное учреждение Российский онкологический научный центр им. Н.Н. Блохина РАМН КЛЕТОЧНАЯ ЛИНИЯ МЕЛАНОМЫ ЧЕЛОВЕКА mel Me, ИСПОЛЬЗУЕМАЯ ДЛЯ ПОЛУЧЕНИЯ ПРОТИВООПУХОЛЕВЫХ ВАКЦИН

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2504010B1 (fr) * 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4808704A (en) * 1981-09-30 1989-02-28 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to cell surface antigens of human malignant melanoma
US4806628A (en) * 1982-11-30 1989-02-21 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies against melanocytes
US4591572A (en) * 1983-04-01 1986-05-27 Sloan-Kettering Institute For Cancer Research Pigmentation associated, differentiation antigen of human melanoma and autologous antibody
USH819H (en) * 1984-04-30 1990-09-04 The United States Of America As Represented By The Secretary Of Energy Palladium-109 labeled anti-melanoma monoclonal antibodies
US4851510A (en) * 1984-11-30 1989-07-25 Wadley Technologies, Inc. Monoclonal antibodies to novel melanoma-associated antigens
US4798790A (en) * 1985-07-18 1989-01-17 Sloan-Kettering Institute Monoclonal antibody specific for a pigmentation associated antigen
US5141742A (en) * 1986-02-07 1992-08-25 Oncogen Vaccines against melanoma
US5262177A (en) * 1986-02-07 1993-11-16 Oncogen Recombinant viruses encoding the human melanoma-associated antigen
US5009995A (en) * 1986-10-27 1991-04-23 Sloan-Kettering Institute For Cancer Research Monoclonal antibodies to melanoma cells
US5059523A (en) * 1988-05-02 1991-10-22 Sloan-Kettering Institute For Cancer Research Cell-surface glycoproteins of human sarcomas
US5009495A (en) * 1989-05-26 1991-04-23 Williams Robert D Hinge for eyeglasses
EP0444181B2 (en) 1989-08-04 2010-11-24 Bayer Schering Pharma Aktiengesellschaft C-erbb-2 external domain: gp75
IE20000918A1 (en) * 1990-03-22 2001-05-30 Sloan Kettering Inst Cancer GP75 As a Tumor Vaccine for Melanoma
US5262117A (en) * 1990-10-12 1993-11-16 Centro Sviluppo Settori Impiego S.R.L. Process for preparing thermoinsulating and/or structural formed articles and products so obtained
US6180604B1 (en) * 1996-08-21 2001-01-30 Micrologix Biotech Inc. Compositions and methods for treating infections using analogues of indolicidin

Also Published As

Publication number Publication date
EP0522078A1 (en) 1993-01-13
US20050037462A1 (en) 2005-02-17
SK282873B6 (sk) 2003-01-09
ES2141089T3 (es) 2000-03-16
PL169105B1 (pl) 1996-06-28
IE20000918A1 (en) 2001-05-30
DE69131829T2 (de) 2000-06-15
CA2078773A1 (en) 1991-09-23
EP0522078A4 (en) 1993-05-26
IE910820A1 (en) 1991-09-25
NO311366B1 (no) 2001-11-19
PL168235B1 (pl) 1996-01-31
AU660412B2 (en) 1995-06-29
FI924222L (fi) 1992-09-21
EP0522078B1 (en) 1999-12-08
CZ290278B6 (cs) 2002-07-17
JPH06501837A (ja) 1994-03-03
AU7690691A (en) 1991-10-21
WO1991014775A1 (en) 1991-10-03
NO923659D0 (no) 1992-09-21
JP3336006B2 (ja) 2002-10-21
ATE187493T1 (de) 1999-12-15
PL169168B1 (pl) 1996-06-28
HU218416B (hu) 2000-08-28
HK1014732A1 (en) 1999-09-30
HUT62934A (en) 1993-06-28
PL289550A1 (en) 1992-07-27
CA2078773C (en) 2001-07-03
CS76091A3 (en) 1992-02-19
EP0965640A1 (en) 1999-12-22
JP2002241314A (ja) 2002-08-28
FI113786B (fi) 2004-06-15
PT97103B (pt) 1999-02-26
US6168946B1 (en) 2001-01-02
GR3032804T3 (en) 2000-06-30
NZ237532A (en) 1993-03-26
DK0522078T3 (da) 2000-06-13
DE69131829D1 (de) 2000-01-13
FI924222A0 (fi) 1992-09-21
PT97103A (pt) 1991-12-31

Similar Documents

Publication Publication Date Title
NO923659D0 (no) Gp75 som en tumorvaksine for melanom
HUP0302532A2 (hu) Petefészekrák terápiájában és diagnosztizálásában alkalmazható készítmények és eljárások
DE60044665D1 (de) Her2/neu fusionsproteine
NO20022531L (no) Vaksine for forebyggelse og behandling av Alzheimer- og amyloidrelaterte sykdommer
RU2009130954A (ru) Применение белков теплового шока для улучшения терапевтического эффекта невакционного лечебного воздействия
HUP0002095A2 (hu) Vegyületek prosztatarák immunterápiás kezelésére és alkalmazásuk
IL141868A0 (en) Novel methods for therapeutic vaccination
IL125590A (en) Peptide immunogens, process for their preparation and use thereof as vaccines against allergies
ATE391726T1 (de) Modifiziertes gp100 und dessen verwendung
DE58904760D1 (de) Virusmodifizierte tumorvakzinen fuer die immuntherapie von tumormetastasen.
DE3789082D1 (de) Expression eines tumorspezifischen Antigens eines rekombinanten Virusvektors sowie dessen Anwendung zur versorgenden oder heilenden Behandlung des entsprechenden Tumors.
CA2143823A1 (en) Retro-, inverso - and retro-inverso synthetic peptide analogues
EP0934083A4 (en) IMPROVED VACCINES
WO1999065517A3 (en) Therapeutic compositions that produce an immune response by altering the antigen
PL1684801T3 (pl) Rekombinowana toksyna cyklazy adenylanowej indukuje odpowiedzi komórek T przeciwko antygenom nowotworowym
EA200100395A1 (ru) Фармацевтическая композиция, содержащая фрагменты днк, кодирующей антигенный белок, обладающая противоопухолевым действием
CA2440610A1 (en) Induction of tumor immunity by variants of folate binding protein
EA200300638A1 (ru) Вакцинная композиция, содержащая трансформирующий фактор роста альфа
CY1105179T1 (el) Φαρμακα για την ανοσοθepαπεια κακοηθων ογκων
NO20005321L (no) Vertskodet protein uttrykt i Mareks sykdoms (MDV) infiserte celler og antistoffer til dette
CY1108790T1 (el) Συνθεσεις για τη θεραπεια και διαγνωση ωοθηκικου καρκινου
RU2003107017A (ru) Копозиции и способы терапии и диагностики злокачественных опухолей, связанных с her-2/neu
YU24401A (sh) Novi postupci za terapeutsku vakcinaciju